Treatment Patterns of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis

被引：0
|
作者：
Jin, Yinzhu [1 ]
Liu, Jun [1 ]
Desai, Rishi [1 ]
Kim, Seoyoung [1 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2022年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1761
引用
收藏
页码：3476 / 3479
页数：4
相关论文
共 50 条
  • [31] A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis
    Sen, Rouhin
    Riofrio, Maria
    Singh, Jasvinder A.
    EXPERT OPINION ON DRUG SAFETY, 2024, : 687 - 714
  • [32] Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
    Yen, J. -H.
    BIOMEDICINE & PHARMACOTHERAPY, 2006, 60 (10) : 688 - 692
  • [33] SUSTAINABILITY OF RESPONSE TO UPADACITINIB AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    van Vollenhoven, Ronald
    Hall, Stephen
    Wells, Alvin F.
    Meerwein, Sebastian
    Song, Yanna
    Suboticki, Jessica L.
    Fleischmann, Roy
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 29 - 30
  • [34] Medication adherence to disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis at Assiut University Hospital, Egypt
    Safaa A. Mahran
    Tayser Mohamed Khedr
    Esraa Moustafa Mohammed
    Eman Mohamed Hussein El-Hakeim
    Egyptian Rheumatology and Rehabilitation, 47
  • [35] Development of a nursing practice scale for rheumatoid arthritis treatment with biological disease-modifying anti-rheumatic drugs
    Song, Fang
    Nakatani, Hisae
    Sugiyama, Eiji
    Hirata, Shintaro
    MODERN RHEUMATOLOGY, 2024, 34 (03) : 479 - 487
  • [36] Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Fan, Junyu
    Jiang, Ting
    He, Dongyi
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [37] Medication adherence to disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis at Assiut University Hospital, Egypt
    Mahran, Safaa A.
    Khedr, Tayser Mohamed
    Mohammed, Esraa Moustafa
    El-Hakeim, Eman Mohamed Hussein
    EGYPTIAN RHEUMATOLOGY AND REHABILITATION, 2020, 47 (01)
  • [38] Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs
    van Vollenhoven, Ronald
    Hall, Stephen
    Wells, Alvin
    Meerwein, Sebastian
    Song, Yanna
    Suboticki, Jessica
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3534 - 3536
  • [39] SUSTAINABILITY OF RESPONSE TO UPADACITINIB AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Van Vollenhoven, R.
    Hall, S.
    Wells, A. F.
    Meerwein, S.
    Song, Y.
    Suboticki, J.
    Fleischmann., R. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1290 - 1291
  • [40] Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
    Bianchi, Gerolamo
    Carletto, Antonio
    Epis, Oscar Massimiliano
    Scioscia, Crescenzio
    Semeraro, Angelo
    Bianchino, Laura
    Bazzichi, Laura
    Lapadula, Giovanni
    Sinigaglia, Luigi
    Lo Monaco, Andrea
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1045 - S1046
12345